ClinicalTrials.gg
CompletedNCT06089265KHKi in HFIUpdated Jan 24, 2024

Ketohexokinase Inhibition in Hereditary Fructose Intolerance

A Phase 2 interventional study of PF-06801591 in HFI, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Maastricht University Medical Center · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hereditary fructose intolerance (HFI) is a rare inborn error of metabolism. Patients with HFI develop acute abdominal pain, nausea, vomiting, hypoglycemia and proximal tubular dysfunction upon consumption of a fructose containing food product. In rare cases, (prolonged) fructose consumption can even lead to liver and kidney failure. Patients with HFI are therefore treated with a lifelong fructose-restricted diet. Animal studies have shown that the clinical manifestations of HFI are abrogated upon inhibition of ketohexokinase (KHK), the enzyme that catalyses the first step in fructose metabolism.

Recently, PF-06835919, a KHK inhibitor (KHKi), was developed as a new treatment for non-alcoholic fatty liver disease. The compound was well tolerated in several phase II clinical trials.

It is hypothesized that PF-06835919 is also effective in patients with HFI.

Read the detailed description

Rationale: Hereditary fructose intolerance (HFI) is a rare inborn error of metabolism. Patients with HFI develop acute abdominal pain, nausea, vomiting, hypoglycemia and proximal tubular dysfunction upon consumption of a fructose containing food product. In rare cases, (prolonged) fructose consumption can even lead to liver and kidney failure. Patients with HFI are therefore treated with a lifelong fructose-restricted diet. Animal studies have shown that the clinical manifestations of HFI are abrogated upon inhibition of ketohexokinase (KHK), the enzyme that catalyses the first step in fructose metabolism.

Recently, PF-06835919, a KHK inhibitor (KHKi), was developed as a new treatment for non-alcoholic fatty liver disease. The compound was well tolerated in several phase II clinical trials.

It is hypothesized that PF-06835919 is also effective in patients with HFI. Objective: To study the effects of PF-06835919 on fructose tolerance and intrahepatic lipid content in patients with HFI. Study design: open-label, pilot study Study population: three adult patients with HFI will be treated with PF-06835919. Five adult healthy individuals will be included (but not be treated) as a reference. Intervention (if applicable): Patients receive once daily (in the morning) three tablets of 100 mg PF-06835919 for 9 days. They will subsequently be gradually exposed to increasing doses of either oral fructose or glucose (in a blinded fashion). Healthy individuals will only undergo oral fructose exposure, as a reference. Main study parameters/endpoints: Intrahepatic lipid content assessed by proton magnetic resonance spectroscopy (at baseline and completion), intestinal fructose tolerance (after oral fructose in comparison to oral glucose), hepatic fructose tolerance (serum glucose and phosphate after oral fructose in comparison to healthy individuals) and renal fructose tolerance (urinary glucose, phosphate, pH and amino acids after oral fructose in comparison to healthy individuals). Nature and extent

02

Conditions studied

  • HFI
03

In context

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Participants are able to provide signed and dated written prior to any study specific procedures
  • Use of effective (only applicable to premenopausal women; a pregnancy test will be performed in these women at baseline)
  • Aged ≥ 18 years

Exclusion Criteria:

  • Diabetes mellitus
  • Pregnancy
  • Patients with congestive heart failure and/or severe renal and or liver insufficiency
  • Uncontrolled hypertension
  • Previous enrolment in a clinical study with an product during the last 3 months or as judged by the investigator which would possibly hamper our study results
  • Use of drugs that inhibit organic anion transporting polypeptide B1 (OATPB1) transporters (e.g. rifampicin, gemfibrozil, ciclosporine, erythromcyin and clarithromycin)*
  • Treatment with irinotecan* Any for MRI scanning*
  • Subjects who do not want to be informed about unexpected medical findings

    • Exclusion criterion for HFI patients only.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    HFI patients

    HFI participants will receive PF-06835919 for 9 days. Dosage; once daily 300 mg PF-06835919 in the form of 3 tablets, oral.

    Drug: PF-06801591

  • No intervention
    Healthy controls

    Healthy controls will receive no intervention, but a single fructose tolerance test.

Interventions

  • Active ketohexokinase inhibitor

    Also known as: KHKi

06

What researchers measure

Primary outcomes

  1. Intestinal Fructose tolerance,

    a visual analog scale from 1-10 for abdominal pain will be used. Additional every 5 minutes the participant will be asked if he/she is nauseous, and more, less or similar nauseous as 5 minutes before.

    Time frame: 9 days

  2. Intestinal Fructose tolerance,

    Every 5 minutes the participant will be asked if he/she is nauseous, and more, less or similar nauseous as 5 minutes before.

    Time frame: 9 days

  3. Renal Fructose tolerance

    Urinary pH

    Time frame: 9 days

  4. Renal Fructose tolerance

    Glucose content, mmol/L

    Time frame: 9 days

  5. Renal Fructose tolerance

    Phosphate content mmol/L

    Time frame: 9 days

  6. Renal Fructose tolerance

    Amino acid content mmol/L

    Time frame: 9 days

  7. Hepatic fructose tolerance

    Serum glucose levels, mmol/L

    Time frame: 9 days

  8. Hepatic fructose tolerance

    Serum phosphate levels, mmol/L

    Time frame: 9 days

Secondary outcomes

  1. Intrahepatic lipid content

    measured using 1H-MRS at baseline and completion

    Time frame: 9 days

  2. Blood pressure

    measured at baseline and completion. Both systolic and diastolic pressure will be assessed

    Time frame: 9 days

  3. Glycosylated transferrin

    measured at baseline and completion.

    Time frame: 9 days

07

Study locations

1 site
  • Maastricht University Medical centre
    Maastricht, Limburg 6202AZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Data can be obtained with the PI on request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Nov 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
Oct 18, 2023
StartActual
Jun 15, 2023
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 30, 2023
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06089265
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Jun 15, 2023
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023
Last update
Jan 24, 2024

Study contacts

Patrick Schrauwen, PhD
principal investigator · Maastricht University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sasanlimab

Start the discussion